Tags : Renal Cell Carcinoma

Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Receives EU Approval for 1L Intermediate- and Poor-Risk Advanced RCC

Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) + Low-Dose Yervoy (ipilimumab) Receives

Vartika Singh January 15, 2019

Shots: The approval is based on P-III CheckMate-214 study results assessing Opdivo (3mg/kg) + low-dose Yervoy(1mg/kg) vs sunitinib (50mg, qd) in patients with previously untreated advance RCC P-III Checkmate-214 study […]readmore

1
2

Copyright © 2020 Digiqole. All Right Reserved.